ARCHIVES

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

This article is from The Cancer Letter archive.

Vol. 15 No. 30 | July 28, 1989

Download PDF Visit The Full Archive

Related Articles

Single-Letter Mutation Found Responsible For Waldenstrom’s

December 30, 2011

NIH Reauthorization Still Lingering, Bills ‘Tie Hands’ Of NCI Director

October 18, 1991

Richard Pestell To Lead Lombardi Cancer Cente

September 6, 2002

Pharmacogenomics May Lead To Individualized Treatment

June 25, 2004

340B Drug Discount Program: HRSA Defends Orphan Drug Rule

June 20, 2014

Breast MRI Recipients More Likely To Choose Mastectomy

July 31, 2009